Dub Timothée, Solastie Anna, Hagberg Lotta, Liedes Oona, Nohynek Hanna, Haveri Anu, Virta Camilla, Vara Saimi, Lasander Mervi, Ekström Nina, Österlund Pamela, Lind Katja, Valtonen Hanna, Hemmilä Heidi, Ikonen Niina, Lukkarinen Timo, Palmu Arto A, Melin Merit
Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Front Med (Lausanne). 2022 Jul 28;9:876532. doi: 10.3389/fmed.2022.876532. eCollection 2022.
Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time.
In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein.
SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively.
Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases.
家庭传播研究为评估严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的二代发病率(SAR)和抗体随时间的持续性提供了机会。
2020年春季,我们邀请确诊的2019冠状病毒病(COVID-19)病例及其家庭成员进行四次访视,在索引病例发病后的28天内采集鼻咽和血清样本。我们根据SARS-CoV-2中和抗体(NAb)的存在情况计算SAR,并评估针对SARS-CoV-2刺突糖蛋白和核蛋白的NAb及IgG抗体(Ab)的持续性。
SAR为45%(39/87),包括35例有症状的二代病例。在最初的28天随访期间,62%(80/129)的参与者产生了NAb。在血清转化者中,90%(63/70)、85%(63/74)和78%(45/58)在索引病例发病后3、6和12个月时仍对早期B谱系SARS-CoV-2具有NAb。抗刺突IgG Ab在血清转化参与者中3、6和12个月后的持续率分别为100%(69/69)、97%(72/74)和93%(55/59),而抗核蛋白IgG Ab水平下降更快,分别在99%(68/69)、78%(58/74)和55%(39/71)的参与者中持续存在。
在家庭中检测到COVID-19病例后,其他成员感染风险很高。大多数情况下,针对早期B谱系SARS-CoV-2的NAb至少持续一年。